Publication

FDG-PET-CT identifies histopathological non-responders after neoadjuvant chemotherapy in locally advanced gastric and cardia cancer: cohort study.

Journal Paper/Review - May 9, 2018

Units
PubMed
Doi
Contact

Citation
Schneider P, Eshmuminov D, Rordorf T, Vetter D, Veit-Haibach P, Weber A, Bauerfeind P, Samaras P, Lehmann K. FDG-PET-CT identifies histopathological non-responders after neoadjuvant chemotherapy in locally advanced gastric and cardia cancer: cohort study. BMC cancer 2018; 18:548.
Type
Journal Paper/Review (English)
Journal
BMC cancer 2018; 18
Publication Date
May 9, 2018
Issn Electronic
1471-2407
Pages
548
Brief description/objective

Pathologic response to neoadjuvant chemotherapy (neoCTX) is a prognostic factor in many cancer types, and early prediction would help to modify treatment. In patients with gastric and esophagogastric junction (AEG) cancer, the accuracy of FDG PET-CT to predict early pathologic response after neoadjuvant chemotherapy (neoCTX) is currently not known.